Moalifeplus Signs First Fixed-Revenue Contract for Physical AI Data Center

원본보기 아이콘

Moalifeplus announced on February 19 that it has fired the starting gun for a transition in its business structure by signing the first fixed annual revenue contract for its next-generation AI infrastructure business, the "Physical AI Data Center."

According to the company, the key point of this business is that, starting in February, it has shifted from a simple technology verification or pilot test phase to an operating revenue model based on recurring billing, through the signing of fixed annual revenue contracts.

The Physical AI Data Center is a distributed AI infrastructure system that enables real-time computation, analysis, and control at data-generation sites. By reducing dependence on central cloud systems and enabling on-site, customized AI training, it is seeing rising demand in industries that require high-precision computation, such as manufacturing, bio, and healthcare.

A company representative explained, "This revenue recognition signifies not only the commercial viability of the technology, but also that the business has begun to expand under a recurring billing structure," adding, "We will further advance it into a structure that includes operation, maintenance, and module expansion."

Meanwhile, the company recently announced that it has been selected for the 2026 Joint Technology Development (R&D) Program organized by the Korea Food Industry Cluster Promotion Agency.

The goal of this project is to "identify the functional efficacy of improving osteoporosis and develop individually approved raw materials for health functional foods." Existing first-line osteoporosis treatments such as bisphosphonates are targeted drugs that act directly on bone cells, and have posed issues such as increased risk of femoral fractures and cardiovascular diseases, and the possibility of relapse upon discontinuation of treatment. Through this project, however, by scientifically elucidating the mechanism of restoring bone metabolism balance based on anti-inflammatory and immune homeostasis regulation and modulation of the JAK-STAT signaling pathway, it is expected to move beyond being a simple supplementary health ingredient and establish a new paradigm grounded in disease mechanisms.

A company representative stated, "This is a high-performance mineral-binding material based on our proprietary PGA platform technology," and added, "We expect this project to serve as a turning point that goes beyond simple research funding to accelerate the registration and commercialization of individually approved raw materials. Furthermore, in the mid- to long-term, we plan to pursue expansion into the pharmaceutical development stage based on the accumulated non-clinical data."

The company explained that, in parallel with expanding its AI infrastructure business, it plans to build a long-term and sustainable profit model by establishing a stabilizing cash-flow role from its existing consumer goods segments, including cosmetics and health functional foods.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.